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Background: The clinical significance of common histological parameters in acute interstitial 
nephritis (AIN) is uncertain. We aimed to evaluate the utility of histology in predicting clinical 
outcomes in patients with AIN.  
Methods and results: Adult renal biopsies yielding a diagnosis of AIN between 2000 and 
2015 were re-examined. Patients were divided into groups based on: 1) the percentage of 
non-fibrotic cortex containing inflammation (NFI-score), (NFI-1=0-24%, NFI-2=25-74%, NFI-
3=75-100%), and 2) the percentage of cortex containing tubular atrophy (TA score), (TA1=0-
9%, TA2=10-24%, TA3=25-100%). The primary outcome was a composite of 50% 
reduction in serum creatinine (sCr) or an eGFR >60 ml/min/1.73m2 1-year post-biopsy. From 
a total of 2817 native renal biopsies, there were 120 patients with AIN and adequate data for 
analysis. Of these, 66 (56%) achieved the primary outcome. On univariable logistic 
regression, NFI-3 was associated with a 16 times increased likelihood of achieving the 
primary outcome compared to NFI-1 (OR 16 (95% CI 5.2-50)). In contrast, TA3 were 
associated with a 90% reduced likelihood of achieving the primary outcome compared to 
TA1 (OR=0.10 (95%CI 0.0-0.3)). Maximal clinical utility was achieved by combining TA and 
NFI into a single prognostic ‘TANFI’ score, which had an independent predictive effect on 
the primary outcome in a multivariable regression model consisting of age, sex, baseline sCr 
and identified drug cause.   
Conclusions: In patients with biopsy-proven AIN, a lower percentage of cortical tubular 
atrophy and, paradoxically, a higher percentage of inflammation in non-fibrosed cortex were 
associated with an increased likelihood of a positive clinical outcome. 
 






Acute interstitial nephritis (AIN) is a recognised cause of acute kidney injury (AKI), and the 
incidence of AIN is increasing worldwide.(1–3) Definitive diagnosis requires renal biopsy. 
AIN is the resulting diagnosis in 1-3% of all renal biopsies and 6.5-35% of biopsies 
performed in the context of AKI.(4,5) Despite this, there is a lack of consensus regarding 
precise histological diagnostic criteria and the clinical significance of common histological 
findings is uncertain.  
 
Two recent studies define AIN as “the presence of prominent interstitial inflammation in the 
non-fibrotic cortex and tubulitis”.(3,6) Other definitions share similar themes but vary on  
whether the interstitium containing the infiltrate can be fibrotic or not,(7) and on the presence 
of co-existent tubulitis and/or oedema (4,5,8,9).  Beyond diagnosis, the role of histology in 
prognostication in AIN is also unclear. Several small studies have explored the relationship 
between histological findings and clinical outcomes in AIN with conflicting results.(10–13) 
These 4 studies each included 30 patients or fewer and were performed over 20 years ago, 
over which time the landscape of AIN has changed.(3) More recent studies have largely 
focused on the potential influence of corticosteroid treatment in the management of AIN.(14) 
However, Muriithi et al found that increased tubular atrophy correlated with poor response to 
corticosteroids.(3)  While in a multi-centre retrospective study of steroid-treated AIN, the 
presence of >50% interstitial fibrosis associated with a reduced likelihood of renal 
recovery.(15)  
 
Beyond tubular atrophy and interstitial fibrosis, the prognostic significance of other 
histological variables in AIN, in particular interstitial inflammation, has not been assessed. 
Furthermore, given the wide variation in clinical outcomes in patients with AIN (ranging from 
complete recovery of renal function to established renal failure), a prognostic score to guide 
management decisions and patient expectations is desirable.  
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The aim of the present study is to evaluate the utility of histology in predicting clinical 
outcomes in a cohort of patients with AIN.  
 
Materials and methods  
Patient population  
All adult patients with a first native renal biopsy diagnostic of AIN between 2000 and 2015 in 
the Glasgow Renal & Transplant Unit were identified. This unit serves a defined population 
of 1.5 million, with the predominant ethnic group being white. Clinical data were collected 
retrospectively using the West of Scotland Electronic Patient Record. Baseline data at time 
of biopsy, including patient demographics, serum creatinine (sCr), urine protein:creatinine 
ratio (uPCR), serum albumin, serum eosinophil count, medications and biopsy report were 
collected. Clinical correspondence was reviewed to identify the aetiology of AIN where 
known. Outcome data including sCr and need for renal replacement therapy were collected 
at 12 +/- 3 months from time of biopsy. Estimated glomerular filtration rate (eGFR) was 
calculated using the Chronic Kidney Disease Epidemiology Collaboration equation.(16) The 
primary outcome was a composite of 50% reduction in sCr or an eGFR of >60 
ml/min/1.73m2 at 12 months from the time of biopsy. Instances of 50% reduction in sCr due 
to dialysis were discounted. The secondary outcome was an eGFR <30 ml/min/1.73m2 at 12 
months from biopsy. Caldicott Guardian Approval was granted for this project.  
 
Renal histology 
Kidney biopsies were processed as standard, with hematoxylin and eosin, periodic acid–
Schiff, Masson trichrome, and Jones methenamine silver stains used for light microscopy. 
Additional sections were routinely examined using immunofluorescence and electron 
microscopy. Histological diagnosis of AIN was based on the presence of an interstitial 
inflammatory cell infiltrate. All biopsies were reviewed by a single pathologist without 
knowledge of the clinical outcome and scored for the percentage of total and non-fibrosed 
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cortex containing inflammation, the percentage of cortex with tubular atrophy, and the 
presence or absence of, granulomas, prominent eosinophils, prominent neutrophils and 
oedema. The presence and severity of tubulitis and the density of the infiltrate (mild, 
moderate, severe) was recorded. The number of glomeruli, the number of sclerosed 
glomeruli and the severity of arteriosclerosis was also recorded. Guidance for histological 
analysis is included in supplementary material (S1).  
 
Statistical analysis 
Descriptive statistics are reported as mean and standard deviation or median and 
interquartile range for normally distributed and skewed variables, respectively. Continuous 
histological variables (such as the percentage of non-fibrosed cortex containing inflammation 
(NFI), and the percentage of tubular atrophy (TA) were divided into groups based on the 
spread of data. Kruskal-Wallis tests were used to compare median sCr between groups at 
baseline and 1 year. Binary logistic regression was applied to assess the ability of individual 
histological and baseline features to predict the clinical outcomes. Histological variables 
were entered into a multivariable logistic regression model and then excluded in a stepwise 
manner until only histological variables that retained independent statistical significance 
(p<0.05) remained. Age, sex, baseline sCr and the presence or absence of an identified 
drug cause were included in the model on clinical justification. Overall model fit was 
assessed using Nagelkerke’s R2 and C-statistic, with an increase in both values suggesting 
a better model fit. Correlation between histological variables was assessed using Spearman-
Rank correlation. Pearson Chi squared tests or Mann Whitney U-test were used as 
appropriate to compare results depending on corticosteroid therapy. All analyses were 
performed using SPSS 25.0 (IBM, NY) and a conventional significance level of <0.05 was 
used. Figures were generated using Microsoft Excel® 2011. 
 
Results  
Patient population  
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A total of 2817 native renal biopsies were performed within our centre between 2000 and 
2015, of which 147 (5.2%) were first native renal biopsies yielding a diagnosis of AIN. Of 
these patients, 27 were excluded (12 patients died within the first year of follow-up, 7 had 
faded pathology slides, 4 had insufficient clinical data available and 4 had dual renal 
pathology) leaving 120 patients for analysis. 97 (81%) patients received corticosteroids for 
the treatment of AIN. Table 1 shows baseline features.  
 
Outcomes 
A total of 66 (55%) patients achieved the primary outcome of a composite of 50% reduction 
in sCr or an eGFR >60 ml/min/1.73m2 at 1 year. Three of these patients had required 
dialysis at time of diagnosis.  
 
A total of 36 (30%) patients achieved the secondary outcome of an eGFR <30ml/min/1.73m2 
at 1 year. Only 1 of these patients had an eGFR greater than 30ml/min/1.73m2 at time of 
biopsy. The percentage change in sCr in these patients ranged from a 79% improvement to 
a 38% deterioration. 5 of these patients went on to require long-term renal replacement 
therapy (ranging from between 5 months and 4 years post-biopsy). 
 
Drug cause  
 
75 (63%) patients had a suspected drug cause identified (see supplementary material for 
details (S2)). There was no difference in composite primary outcome between those who did 
and did not have a drug cause identified (p=0.30).  
 
Histological variables of interest 
 
1) Inflammation in non-fibrotic cortex (NFI) 
 
Patients were divided into 3 groups based on NFI 0-24%, 25-74%, and 75-100% and 
awarded a score of NFI-1, NFI-2, and NFI-3, respectively.  As NFI-score increased from 1 to 
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3, sCr at baseline increased (table 2, Kruskal-Wallis H 17.1, p<0.001), while sCr at 1 year 
decreased (table 2, Kruskal-Wallis H 26.4, p<0.001). On univariable logistic regression, an 
NFI-score of 3 was associated with a 16 times increased likelihood of achieving the primary 
composite outcome compared to a score of 1 (OR 16.2 (95% CI 5.2-50.1, p<0.001)). There 
was no difference between an NFI-score score of 1 compared to an NFI-score of 2 in terms 
of primary outcome (OR 2.6 95% CI 0.96-6.5, p=0.051). 
 
2) Tubular atrophy (TA) 
Patients were divided into 3 groups based on TA of 0-9%, 10-24% and 25-100% to correspond 
to score of TA1, TA2, and TA3, respectively. As TA score increased from 1 to 3, there was no 
difference in sCr at biopsy (table 2, Kruskal-Wallis H 0.79, p=0.68), but sCr at 1 year increased 
(table 2, Kruskal-Wallis 33.3, p<0.001). On univariable logistic regression, TA2 and TA3 were 
associated with 75% and 90% reduced likelihood of achieving the primary outcome compared 
to TA1 (OR 0.25 (95% CI 0.08-0.75), p=0.013 for TA2; OR=0.10 (95%CI 0.03-0.33) p<0.001 
for TA3).  
 
3) Combination of TA and NFI 
NFI=1-3 and TA=1-3 had a moderate negative correlation with a coefficient of -0.38, 
p<0.001). Figure 1 shows the proportion of patients who achieved the primary outcome, 
stratified by TA-score and NFI-score. Patients with TA3 and NFI-1 were least likely to 
achieve a favourable renal outcome.  A prognostic index score (TANFI) was created by 
combining TA score with inverse NFI score (i.e. NFI-3 = 1 point, NFI-1 = 3 points) awarding 
each patient a score of between 2 and 6. As TANFI score increased, the proportion of 
patients achieving a favourable renal outcome decreased (figure 2; also supplementary 
material S3). On univariable logistic regression, a TANFI score of 4, 5 or 6 associated with a 
92-99% reduced likelihood of the primary outcome compared to a TANFI score of 2 (OR for 
TANFI-4 = 0.08 (95% CI 0.01-0.63), OR for TANFI-5 = 0.03 (95% CI 0.004-0.29), OR for 
TANFI-6 = 0.01 (95% CI 0.001-0.12). The TANFI score accounted for 35% of the variability 
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in primary outcome (Nagelkerke’s R2 = 0.35) with a C-statistic of 0.79.  When the pre-
specified clinical variables of age, sex, baseline sCr and identified drug cause were 
accounted for, TANFI score had an independent predictive effect on the primary outcome on 
multivariable logistic regression (table 3). The multivariable model accounted for 47% of the 
variation in primary outcome (Nagelkerke R2 0.47), with a C-statistic of 0.86.   
 
When the same variables were entered into a model to predict the secondary outcome, 
TANFI score independently associated with the secondary outcome (table 3). The direction 
of effect was inverted in comparison to the primary composite outcome, such that higher 
TANFI scores associated with a greater likelihood of the secondary outcome. Overall the 
model accounted for 41% of the variation in secondary outcome (Nagelkerke R2 0.41) with a 
C-statistic of 0.84. 
 
4) Other histological findings 
Additional histological features including the percentage of inflammation in total cortex (ti), 
the presence of tubulitis, oedema, granulomas, eosinophils, neutrophils, proportion of 
sclerosed glomeruli and severity of arteriosclerosis were reported (table 1). Ti score, the 
severity of tubulitis, the presence of oedema, and the proportion of glomeruli that were 
sclerosed were all significantly associated with primary outcome on univariable analysis. The 
presence of granulomas, prominent eosinophils, prominent neutrophils and arteriosclerosis 
was not associated with outcome on univariable analysis, nor was the density of the 
infiltrate. No additional histological variable achieved statistical significance in multivariable 
analysis with TA and NFI (supplementary material S1, S4-S11).  
 
5) Role of corticosteroids 
97 (81%) patients received corticosteroids for the treatment of AIN. Median duration of 
steroid treatment was 5 months. There was no difference in median sCr at baseline or at 1 
year between those who did and did not receive corticosteroids (Mann-Whitney U test 
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p=0.16 and p=0.86, respectively). Of the 97 patients who received corticosteroids, 56 (58%) 
achieved the primary outcome compared to 10 (43%) of the 23 patients who did not receive 
corticosteroids (Chi square 1.53, p=0.22). When patients who did not receive corticosteroids 
were excluded, the histological variables that retained statistical significance in the 
multivariable model did not change (data not shown). Similarly, when corticosteroid therapy 
was added into the multivariable regression model for TANFI, the overall model fit did not 




In this cohort of patients with biopsy-proven AIN, of whom the majority received 
corticosteroid therapy, histological findings at diagnosis associated with renal outcomes at 1 
year. We confirmed previous findings that suggest the likelihood of a favourable renal 
outcome decreases as the degree of tubular atrophy increases. Conversely, we found a 
positive association between the extent of non-fibrotic cortex containing inflammation and 
the likelihood of a favourable renal outcome. Within this cohort, a prognostic score based on 
the severity of tubular atrophy and non-fibrosed inflammation was able to significantly predict  
renal outcome in patients with AIN, even when baseline clinical features are accounted for.   
 
Tubular atrophy and interstitial fibrosis (which is highly correlated to tubular atrophy  
(R=0.98)(17)) are markers of chronic tubulointerstitial damage with recognized prognostic 
implications in a diverse range of conditions.(18–20) Increasing severity of tubular atrophy 
and interstitial fibrosis have been shown to associate with poor renal outcomes in AIN.(3,15) 
Our finding that TA-score is a predictor of poor renal recovery is consistent with these 
studies. However, our finding that even low levels of tubular atrophy (i.e. affecting 10% of 
the renal cortex) associates with a worse renal outcome is novel.  
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The finding that more inflammation in non-atrophic cortex is associated with better outcome 
is novel in the setting of AIN, but it is consistent with The Boston Kidney Biopsy Cohort study 
in which inflammation in non-fibrotic cortex was associated with a 50% reduced likelihood of 
progressive renal disease in a cohort of 676 patients with a diverse range of aetiologies (14 
of whom had AIN).(19) In our cohort, increasing NFI-score associated with higher sCr at 
biopsy (and therefore perhaps mathematically an increased chance of it reducing by 50%) 
and was negatively correlated with tubular atrophy. However, the correlation between NFI-
score and TA-score was not prohibitive for analysis and even when both tubular atrophy and 
baseline sCr were accounted for in the multi-variable model, NFI-score was still 
independently associated with the primary outcome. The predictive capabilities of NFI-score 
are likely explained by the fact it represents salvageable renal cortex affected by a disease 
process, for which the treatment is highly effective. Furthermore, the more aggressive 
phenotype (manifest as higher sCr at biopsy) could prompt a more urgent renal biopsy and 
potentially earlier treatment. Interstitial inflammation in total renal cortex, both fibrotic and 
non-fibrotic was also associated with better outcome (supplementary material S4). Interstitial 
inflammation in AIN thus appears to be highly reversible, regardless of its severity, in 
patients treated with corticosteroid.  
 
In our cohort, 94% received treatment, with 81% prescribed corticosteroids and an additional 
12.5% having a suspected drug cause withdrawn. It was therefore not possible to assess the 
impact of NFI-score on untreated patients, nor was it possible to demonstrate a lower limit of 
NFI-score that is clinically significant (i.e. a diagnostic threshold for AIN). We presume that 
increasing NFI-score above such a threshold in an untreated patient (e.g. contraindication to 
immunosuppression or inability to stop causative drug) would have a negative effect on 
outcome. We believe consensus on more precise histological diagnostic criteria for AIN, 




The clinical utility of scoring tubular atrophy and inflammation in non-fibrotic cortex is 
enhanced when used in combination. The TANFI score is a simple cumulative metric that 
combines NFI and TA which, if validated in an independent cohort, can provide valuable 
information for patients and clinicians regarding prognosis in AIN. Of note, a TANFI score of 
4 consists of a heterogenous group, with some patients at opposite ends of severity in terms 
of fibrosis/inflammation. Further studies are required to examine the potential differential 
association with outcome that may be seen in the component groups of patients with TANFI 
= 4 (i.e. does 1+3 associate differently with outcome compared to a score of 3+1) but the 
subgroups in the present cohort were too small to assess this reliably (Figure 1; 
supplementary material S3). The TANFI score accounted for 35% of the variability in primary 
outcome within this cohort. For comparison, the Oxford Classification of IgA nephropathy 
(MEST-C score), which is an established histological prognostic score, accounts for 19% of 
the variability in outcome in patients with IgA nephropathy.(21)  
 
There is no trial evidence to support the management of AIN. Nevertheless, steroid therapy 
is accepted practice in biopsy-proven AIN, in which sCr is not spontaneously improving. We 
believe that a randomized trial of high-dose versus low dose corticosteroid in patients with 
biopsy-proven AIN would be clinically useful and ethically justifiable as the first step in 
improving the treatment of AIN. Duration of treatment should also be examined. Beyond 
that, the greatest equipoise lies in cases of drug-induced AIN in which withdrawing the 
causative drug may be sufficient and a trial of early, versus delayed, corticosteroid therapy 
would be enlightening. Stratification by histological findings will be essential to translate 
meaningful results into clinical practice. 
 
This study has limitations. It is a single centre, retrospective analysis. We are reassured that 
our population appears representative of other published series of AIN: 5.2% of native renal 
biopsies in our centre revealed AIN, compared to 5.0% (3) and 5.9%(22) in other published 
series, while 61% had a drug cause, compared to 70% in previous reports.(3,4) A single 
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pathologist re-scored the histological variables of interest. We have previously reported inter-
observer reproducibility for TA and total inflammation in a cohort of patients with IgA 
nephropathy as being ‘good’ (ICC 0.88; P = 0.001) and ‘excellent’ (ICC 0.91; P < 0.001), 
respectively.(23) Furthermore, the reproducibility of these measures is widely established in 
transplant biopsies.(24) Nevertheless these results require validation in other cohorts prior to 
their introduction into clinical practice. We believe the inclusion of diverse AIN aetiologies is 
justified and improves the generalizability of the results. We did not observe a difference in 
outcome between patients with and without an identified drug cause. 
 
In patients with biopsy-proven AIN, of whom the majority received steroids, a higher 
percentage of inflammation in non-fibrosed cortex was associated with an increased 
likelihood of a positive clinical outcome. This implies inflammation in AIN is reversible, 
regardless of extent. Consistent with previous findings, increasing percentage of cortical 
tubular atrophy was associated with worse outcome. In combination, NFI and TA have the 
potential to give useful prognostic information in treated patients with AIN. 
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Tables & Figures 




 ALL Corticosteroids  No 
corticosteroids 
p-value 
N=  120 97 (81%) 23 (19%)  
Female (n, %) 73 (61%) 62 (64%) 11 (48%) 0.15 
Age, years (mean, (SD)) 58.2 
(16.3) 
58.0 (15.9) 58.9 (18.8) 0.45 
Serum Creatinine at 




307 (210, 492) 244 (189, 390) 0.16 
Urine protein:creatinine 




67 (25, 109) 42 (14, 58) 0.17 
Serum albumin, g/L 
(mean (SD)) 
35 (6) 36 (8) 34 (6) 0.23 
Serum eosinophil count, 




0.38 (0.3, 0.52) 0.29 (0.20, 0.50) 0.10 
 
Aetiology of TIN 
   
Drug cause identified (n, 
%) 
75 (63%) 59 (61%) 16 (70%) 0.43 
Sarcoid 8 (7%) 8 0  
TINU 8 (7%) 5 3  
Sjogrens 4 (4%) 4 0  
Tuberculosis (TB) 2 (2%) 2** 0  
No cause identified 26 (22%) 22 4  
More than one aetiology* 2 (2%) 0 2  
 
Histology findings 
   
NFI, (median, (IQR)) 50% (20, 
90) 
60% (20, 90) 50% (10, 70) 0.19 
TA, (median, (IQR)) 15% 
(8,30) 
10% (5, 20) 15% (10, 30) 0.81 
TI, (median, (IQR)) 80% (50, 
90) 
90% (50, 90) 70% (30, 80) 0.05 




9 3  
 
0.38 
1 23 9 
2 44 7 
3 21 4 
Granulomas (n, (%)) 31 (26%) 26 5 0.61 
Eosinophils (n, (%)) 18 (15%) 16 2 0.34 
Neutrophils (n, (%)) 20 (17%) 19 1 0.08 
Oedema (n, (%)) 61 (51%) 54 7 0.03 
Glomeruli (median, IQR) 12 (7, 20) 12 (7, 20) 12 (8, 15)  
Percentage of glomeruli 
sclerosed (median, IQR) 
5 (0, 19) 7 (0, 25) 5 (0, 17)  
Arteriosclerosis (n, 
%) 
0 23 (19%) 7 16  
1 39 (33%) 7 32  
2 43 (36%) 8 35  
 15 
3 8 (7%) 0 8  
 
*1 patient had active tuberculosis, sjogrens syndrome and a possible drug cause 
(rifampicin). Another patient had TINU with a co-existent possible drug cause (rosiglitazone).  
**Both patients with active TB received anti-TB therapy in addition to corticosteroids. 
 
P-values were generated using Pearson chi-squared test and Mann Whitney U-test for 
categorical and continuous variables, respectively, both comparing corticosteroids versus no 
corticosteroids. 
 
Abbreviations: SD = standard deviation. IQR – interquartile range. TINU – tubulointerstitial 
nephritis and uveitis, NFI – percentage of non-fibrosed cortex containing inflammation. TI – 






Table 2.  Tables showing serum creatinine (median, intra-quartile range (IQR)) at baseline 
and 1 year depending on groups of NFI-score (A), and TA-score (B), where ‘NFI’ is the 
percentage of non-fibrotic cortex containing inflammation; and ‘TA’ is the percentage of 
cortex containing tubular atrophy. 
 
A) NFI-score 
 NFI-1 (0-24%) NFI-2 (25-74%) NFI-3 (75-100%) 
N= 37 41 42 
sCr at baseline, 



















 TA1 (0-9%) TA2 (10-24%) TA3 (25-100%) 
N= 30 49 41 
sCr at baseline, 



















Abbreviations: NFI = percentage of non-fibrotic cortex containing inflammation. sCr = serum 






Table 3. Table displaying the odds ratios (OR) for the primary outcome (A) and secondary 
outcome (B) based multivariable logistic regression models consisting of pre-specified 
baseline clinical variables and TANFI score. Higher TANFI scores associated with a 
decreased likelihood of achieving the composite primary outcome (50% reduction in sCr or 
eGFR >60 ml/min/1.73m2) and increased likelihood of the secondary outcome (eGFR <30 
ml/min/1.73m2) 
 
a) Multivariable binary logistic regression for composite primary outcome.  
 
 OR 95% CI of 
OR 
Significance 
Male sex - - NS 
Age - - NS 
Drug cause 
identified 
- - NS 
sCr at biopsy 
(per mol/l) 
1.005 1.002-1.008 0.001 
TANFI - - - 
2 - - - 
3   NS 
4   NS 
5 0.05 0.005-0.44 0.008 
6 0.01 0.001-0.14 <0.001 
 
 
b) Multivariable binary logistic regression for secondary outcome.  
 
 OR 95% CI of 
OR 
Significance 
Male sex 0.27 0.08-0.86 0.03 
Age - - NS 
Drug cause 
identified 
- - NS 
sCr at biopsy 
(per mol/l) 
1.004 1.001-1.007 0.007 
TANFI    
2 - - - 
3 - - NS 
4 15.5 1.2-197 0.04 
5 78.3 5.8-1042 0.001 




Abbreviations: sCr = serum creatinine. TANFI = prognostic score ranging from 2-6 based on 





Figure 1. 3-dimensional bar chart showing the proportion of patients achieving the primary 
composite outcome stratified by tubular atrophy (TA) score and inflammation in non-fibrosed 
cortex (NFI) score. Patients with high TA-score and low NFI-score were least likely to 









 NFI-1 NFI-2 NFI-3 
TA1 5/8 3/4 17/18 
TA2 2/10 8/17 17/22 










Figure 2. The percentage of patients who achieved the primary composite outcome of a 50% 
reduction in serum creatinine or an estimated glomerular filtration rate of greater than 60 
ml/min/1.73m2 stratified by TANFI score. The TANFI score is a novel prognostic score ranging 
from 2-6 based on the combined severity of tubular atrophy (TA) and inflammation in non-















TANFI score 2 3 4 5 6 











Supplementary material  
 
 
S1) Instructions for histological analysis 
Inflammation in interstitium should be detectable at x10 magnification, with confirmation at 
x20 if required. Inflammation in the immediate subcapsular zone or immediately next to large 
arteries at the corticomedullary junction was not counted. An area with non-atrophic tubules 
surrounded by fibrotic interstitium was considered not scarred. An interstitial fibrotic area 
with no tubules (especially around sclerosed glomeruli) was considered scarred. A tubule 
was deemed to be atrophic if any of the following features were present: thyroidisation; 
diameter ≤25% of normal with or without thickened basement membrane; diameter <50% of 
normal with thickened basement membrane visible at x10 magnification. 
Granulomas were well defined (obvious at x10 magnification). Tubulitis was scored as 
follows: t1=1-4 mononuclear cells per tubular cross section or 10 epithelial cells; t2=5-10 
mononuclear cells per tubular cross section/10 epithelial cells; t3= more than 10 
mononuclear cells per tubular cross section/10 epithelial cells. 
 
ADDITIONAL RESULTS: 
S2) Drug causes: details 
In all cases of drug induced AIN, the implicated drug was stopped and 59 (79%) patients 
also received corticosteroids. Proton pump inhibitors (PPIs) were identified as the sole 
implicated drug in 31 cases, while non-steroidal anti-inflammatory drugs (NSAIDs) were 
identified as the sole cause in 11 cases. A further 10 cases had exposure to both PPIs and 
NSAIDs. In 15 cases antibiotics were implicated, of which 3 were also exposed to PPIs and 
2 NSAIDS.  In 4 cases mesalazine was identified as the causative drug and in 4 cases other 
drugs were implicated. 
 
S3) Components of TANFI subgroups 
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TANFI scores of 3, 4, and 5 consist of a combination of patients with different individual NFI 
and TA scores. Most notably a TANFI score of 4 consists of a heterogenous group, with 
some patients at opposite ends of severity in terms of fibrosis/inflammation. The figure below 
displays the proportion of patients achieving the primary outcome by TANFI score, including 
their component subgroups.  
 
Supplementary table 1. Proportion of patients achieving the primary outcome by TANFI 
score sub-divided by their component groups 
 
Chart legend: 
(A) NFI 3 + TA 1;  
(B) NFI 2 + TA 1; (C) NFI 3 + TA 2; 
(D)  NFI 1 + TA 1; (E) NFI 2 + TA 2; (F) NFI 3 + TA 3; 
(G) NFI 1 + TA 2; (H) NFI 2 + TA 3;  
(I) NFI 1 + TA 3 
 
NFI and TA associate with the primary outcome in opposite directions. Accordingly the NFI 
score is inverted when used as part of the TANFI score, such that an NFI score of 3 
contributes  1 point to TANFI score, NFI 2 contributes 2 points, and NFI 3 contributes 1 
point. In contrast, TA 3 contributes 3 points, TA 2 contributes 2 points and TA 1 contributes 1 
point to TANFI score. 
 
Supplementary table 3: Number of patients in each TANFI score component 
TANFI score Components of the score (number of patients) 
2 NFI 3 + TA 1 (n=18)   
3 NFI 2 + TA 1 (n=4) NFI 3 + TA 2 (n=22)  
4 NFI 1 + TA 1 (n=8) NFI 2 + TA 2 (n=17) NFI 3 + TA 3 (n=2) 




















TANFI 2 TANFI 3 TANFI 4 TANFI 5 TANFI 6
 22 
6 NFI 1 + TA 3 (n=19)   
 
 
S4) Inflammation in total cortex (ti) 
Patients were divided into 3 groups based on ti of 0-50%, 51- 80% and 81-100% and 
awarded a score of ti-1, ti-2, and ti-3, respectively. As ti-score increased from 1 to 3, serum 
creatinine at baseline increased (supplementary table 1, Kruskal-Wallis H 13.6, p=0.001), 
while serum creatinine at 1 year reduced (supplementary table 1, Kruskal-Wallis H 6.25, 
p=0.04). On univariable logistic regression a ti score of 3 was associated with a 5 times 
increase in the likelihood of achieving the primary outcome compared to ti-1 (OR 5.0 (95% 
CI 2.0-12.5) p=0.001). There was no difference between a ti score of 2 and 1 (OR 1.8 (95% 
CI 0.67-4.8) p=0.25). 
 
Supplementary material table 2.  Table showing serum creatinine (median, intra-quartile range 
(IQR)) at baseline and 1 year depending on the percentage of total cortex, both scarred and 
non-scarred, containing inflammation (ti). 
 
 ti-1 (0-50%) ti-2 (51-80%) ti-3 (81-100%) 
N= 35 31 54 
sCr at baseline, 


















S5) Tubulitis (t) 
On univariable logistic regression, the presence of moderate (t-2) and severe (t-3) tubulitis 
was associated with a 9 and 10 times increase in the likelihood of achieving the primary 
outcome compared to no tubulitis (t-0), respectively (OR 9.2 (95% CI 1.8-46.5) p=0.007 for t-
2; OR 10.6 (95% CI 1.9-60.2) p=0.008 for t-3). There was no difference between mild 




The presence of oedema was associated with a 2.5 times increase in the likelihood of 
achieving the primary composite outcome on univariable logistic regression (OR 2.5 (95% CI 
1.2-5.2) p=0.015). 
  
S7) Granulomas  
Of the 31 patients with granulomas present on biopsy, 13 had a drug cause, 10 no cause 
identified, 5 sarcoid, 1 TINU, and 1 Sjogren’s. A further 1 patient had active TB, Sjogren’s 
syndrome and a possible drug cause. The presence of granulomas was not associated with 
the primary composite outcome on univariable logistic regression (p=0.10).   
 
S8) Cellular Infiltrate 
The presence of prominent eosinophils or neutrophils on biopsy did not predict a drug cause 
and it had no association with the likelihood of achieving the primary outcome, nor did the 
density of the inflammatory cell infiltrate. 
 
S9) Sclerosed glomeruli 
The median percentage of glomeruli that were sclerosed was 5% (IQR 0-19%). On 
univariable analysis, for each unit increase in the percentage of sclerosed glomeruli the 
likelihood of primary outcome reduced by 3% (OR 0.97 (0.95-0.99) p= 0.046) 
 
S10) Arteriosclerosis  
Arteriosclerosis was graded 0-3 (table 1) and was not associated with the primary outcome 
on univariable logistic regression.  
 
S11) Correlation between histological variables 
Supplementary material table 2 shows the bi-variate correlation coefficient for each 
histological parameter. NFI=1-3 and TA=1-3 had a moderate negative correlation with a 
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coefficient of -0.38, p<0.001).Tubulitis and oedema both had a moderate correlation with 
NFI=1-3 of 0.52 and 0.58, respectively (p<0.001 for both). 
 
Supplementary table 3. Bivariable Spearman’s rank correlation coefficient for histological 








Tubulitis Oedema Arteriosclerosis Percentage 
sclerosed 
Glomeruli 
NFI-1-3  .70 -.38 .59 .52 - - 
TI-1-3    .44 .38   
TA-1-3    -.43 -.37 0.27 0.28 
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